New dosing strategy tested for advanced blood cancer drug

NCT ID NCT05064358

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

Summary

This study is testing different dosing schedules for the drug belantamab mafodotin in patients with advanced multiple myeloma that has returned or stopped responding to other treatments. The main goal is to see if changing the dose or timing can reduce serious eye-related side effects while still controlling the cancer. It involves 177 participants and is currently active but not recruiting new patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

West Palm Beach, Florida, 33401, United States
GSK Investigational Site

Kansas City, Missouri, 64114, United States
GSK Investigational Site

New York, New York, 10065, United States
GSK Investigational Site

Chattanooga, Tennessee, 37404, United States
GSK Investigational Site

Nashville, Tennessee, 37203, United States
GSK Investigational Site

Houston, Texas, 77090, United States
GSK Investigational Site

Buenos Aires, C1181ACH, Argentina
GSK Investigational Site

Capital Federal, C1426ANZ, Argentina
GSK Investigational Site

Ciudad Autonoma de Buenos Aire, 1414, Argentina
GSK Investigational Site

Pilar, B1629AHJ, Argentina
GSK Investigational Site

Rosario, S2002, Argentina
GSK Investigational Site

Liverpool, New South Wales, 2170, Australia
GSK Investigational Site

Newcastle, New South Wales, 2298, Australia
GSK Investigational Site

Woodville, South Australia, 5011, Australia
GSK Investigational Site

East Melbourne, Victoria, 3002, Australia
GSK Investigational Site

Joinville, 89201-260, Brazil
GSK Investigational Site

Porto Alegre, 90850-170, Brazil
GSK Investigational Site

Rio de Janeiro, 22271-110, Brazil
GSK Investigational Site

Salvador, 41253-190, Brazil
GSK Investigational Site

São Paulo, 01236-030, Brazil
GSK Investigational Site

São Paulo, 04537-080, Brazil
GSK Investigational Site

Oshawa, Ontario, L1G 2B9, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site

Montreal, Quebec, H4J 1C5, Canada
GSK Investigational Site

Avignon, 84902, France
GSK Investigational Site

Nice, 06189, France
GSK Investigational Site

Orléans, 45100, France
GSK Investigational Site

Cottbus, 03048, Germany
GSK Investigational Site

Dresden, 01307, Germany
GSK Investigational Site

Greifswald, 17475, Germany
GSK Investigational Site

Hamburg, 22763, Germany
GSK Investigational Site

Athens, 106 76, Greece
GSK Investigational Site

Athens, 11528, Greece
GSK Investigational Site

Athens, 12462, Greece
GSK Investigational Site

Rio Patras, 26504, Greece
GSK Investigational Site

Ahmedabad, 380009, India
GSK Investigational Site

Apex Wellness Hospital, 422005, India
GSK Investigational Site

Hyderabad, 500033, India
GSK Investigational Site

Kolkata, 700014, India
GSK Investigational Site

Kolkata, 700156, India
GSK Investigational Site

M S R Nagar Msrit Post, 560054, India
GSK Investigational Site

Pune, 411004, India
GSK Investigational Site

Sushrut Hospital and Research, 400071, India
GSK Investigational Site

Dublin, 8, Ireland
GSK Investigational Site

Dublin, D09 V2N0, Ireland
GSK Investigational Site

Alessandria, 15121, Italy
GSK Investigational Site

Ascoli Piceno, 63100, Italy
GSK Investigational Site

Cagliari, 09121, Italy
GSK Investigational Site

Ferrara, 44124, Italy
GSK Investigational Site

Genova, 16132, Italy
GSK Investigational Site

Meldola FC, 47014, Italy
GSK Investigational Site

Reggio Emilia, 42123, Italy
GSK Investigational Site

Rimini, 47900, Italy
GSK Investigational Site

Mexico City, 03100, Mexico
GSK Investigational Site

Mexico City, 03720, Mexico
GSK Investigational Site

Bydgoszcz, 85-168, Poland
GSK Investigational Site

Gdansk, 80-214, Poland
GSK Investigational Site

Katowice, 40-519, Poland
GSK Investigational Site

Lublin, 20-081, Poland
GSK Investigational Site

Poznan, 60-569, Poland
GSK Investigational Site

Torun, 87-100, Poland
GSK Investigational Site

Warsaw, 02-781, Poland
GSK Investigational Site

Wałbrzych, 58-309, Poland
GSK Investigational Site

Wroclaw, 50-367, Poland
GSK Investigational Site

Hwasun, 58128, South Korea
GSK Investigational Site

Pusan, 49241, South Korea
GSK Investigational Site

Seoul, 03080, South Korea
GSK Investigational Site

Seoul, 06591, South Korea
GSK Investigational Site

Albacete, 02006, Spain
GSK Investigational Site

Barcelona, 08026, Spain
GSK Investigational Site

Córdoba, 140044, Spain
GSK Investigational Site

Girona, 17007, Spain
GSK Investigational Site

Oviedo, 33011, Spain
GSK Investigational Site

Terrassa - Barcelona, 08221, Spain
GSK Investigational Site

Valencia, 46010, Spain
GSK Investigational Site

Bern, 3010, Switzerland
GSK Investigational Site

Taichung, 404, Taiwan
GSK Investigational Site

Taichung, 40705, Taiwan
GSK Investigational Site

Tainan, 704, Taiwan
GSK Investigational Site

Taipei, 100, Taiwan
GSK Investigational Site

Taipei, 112, Taiwan
GSK Investigational Site

Bangkok, 10210, Thailand
GSK Investigational Site

Bangkok, 10330, Thailand
GSK Investigational Site

Chiang Mai, 50200, Thailand
GSK Investigational Site

Khon Kaen, 40002, Thailand
GSK Investigational Site

Leicester, LE1 5WW, United Kingdom
GSK Investigational Site

London, W12 0HS, United Kingdom
GSK Investigational Site

Stoke-on-Trent, ST4 6QG, United Kingdom

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA